Burfiralimab, NORMAL SALINE (0.9% NACL) clinical trials

A Phase 2a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Burfiralimab (hzVSF-v13) added to disease-modifying antirheumatic drugs in patient with moderate to severe Rheumatoid Arthritis

This study is testing a new medicine, Burfiralimab, for people with moderate to severe rheumatoid arthritis. We want to see if it helps reduce joint pain and swelling when added to their usual arthritis medicines. Participants will receive either the new medicine or a dummy treatment.